Key Highlights
- Dr. Ian H. Bellayr joins Diakonos Oncology as Chief Regulatory Officer, bringing extensive experience from the FDA and NIH.
- Dr. Bellayr’s appointment is timely as Diakonos concludes Phase 1 glioblastoma trial and prepares for further clinical trials and commercialization of DOC1021.
- Diakonos’ DOC1021, a dendritic cell vaccine, represents a promising approach in treating late-stage cancers, with ongoing clinical trials for glioblastoma, pancreatic cancer, and angiosarcoma.
Source: Business Wire
Notable Quotes
- “Dr. Bellayr’s regulatory expertise arrives at a crucial time for Diakonos as we conclude our Phase 1 glioblastoma trial. His extensive experience in regulatory strategies and operations will be a critical component as we initiate the remaining clinical trials and ultimate commercialization of DOC1021.” – Mike Wicks, Chief Executive Officer at Diakonos
- “Treatments for late-stage and aggressive cancers still remain a critical unmet need. Diakonos has a unique technology that allows for a personalized cell therapy that is unbiased in its potential to effectively treat multiple indications. I look forward to helping Diakonos move DOC1021 forward through clinical development, creating new treatments that are safe and effective for the most dangerous cancers.” – Dr. Ian H. Bellayr, Chief Regulatory Officer at Diakonos Oncology
